Engineered Osteoclasts for the Treatment and Prevention of Heterotopic Ossification
Annual rept. 30 Sep 2013-29 Sep 2014
WASHINGTON UNIV SEATTLE
Pagination or Media Count:
Heterotopic ossification HO is the abnormal formation of bone in soft tissues and is a frequent complication in patients who have suffered traumatic brain and spinal cord injuries. Currently there are few effective treatments for this condition. This research seeks to develop engineered osteoclasts as a local cell therapy for the prevention andor regression of HO. The goals of this research are to develop proof-of-principle data in excised human HO specimens and in an animal model using existing murine engineered osteoclasts and to develop an off-the-shelf human induced pluripotent stem iPS cell source for clinical translation of this technology. To date we have performed studies to optimize various hydrogel formations as cell delivery vehicles. We will use these hydrogels to retain engineered osteoclasts at sites of HO in vivo. We have also created and validated a lentiviral vector containing an inducible human RANK fusion gene that will be used to develop our human iPS cell source.
- Anatomy and Physiology
- Medicine and Medical Research